Cardiovascular diseases are irreversible. So, it is crucial to prevent them before they appear.
Order your kit today and find out if you are developing a cardiovascular disease before it is too late.
SPINOVIT is a spin-off of UCLouvain funded in January 2022 by Dr Ir Nancy Van Overstraeten with Vives, B2start and SRIW as investment partners.
The product and service were developed in the laboratory of Prof. Jean-Luc Balligand, Institute of Experimental and Clinical Research from UCLouvain.
The Walloon Region supported the creation of the spin-off with a First Spin-Off grant and the proof of concept through the support to our clinical trial PICA, designed by Dr Ir Nancy Van Overstraeten, demonstrating the predictability of our biomarker.
In July 2023, the results from the PICA trial were issued by the Spinovit team: see tab "Our Proof-Of-Concept study" (publication in preparation). The results were reviewed and confirmed by our Scientific Advisory Board chaired by Prof. JL Balligand.
In August 2023, the supporting initial investors decided to abandon their support to Spinovit.
Nancy Van Overstraeten
Scientific Advisory Board
Clinical Trial Manager
"Finally, something to prevent the cardiovascular diseases"
"Security is just 1 mL of blood away."
"I feel safe again"